Bezetabart debotansine
As of the edition of 20 October 2026, Bezetabart debotansine is an antibody drug conjugate: stopped in 2023; acts on CD74.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Antibody drug conjugate
- Registered trials
- 2, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Bezetabart debotansine.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD74 | HLA class II histocompatibility antigen gamma chain | P04233 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sutro Biopharma | Lead sponsor of trials | 2018 to now |
| BioNova Pharmaceuticals | Lead sponsor of trials | 2022 to now |